The US Food and Drug Administration (FDA) has accepted the new drug application (NDA) of the investigational drug ulipristal acetate (UA) for the treatment of abnormal bleeding in women with uterine fibroids. While UA has been available in Europe and Canada for several years, the FDA recently notified for this. “Currently approved treatment options for uterine fibroids are mostly surgical, and these surgeries can take weeks to recover from,” said MD, “That is why a ulipristal acetate is a valuable option for treating uterine fibroids.
For the first time, doctors and patients will have access to an oral treatment option to manage symptoms. I am optimistic that with a new oral treatment option, fewer women will suffer in silence and leave their uterine fibroids untreated.” UA belongs to a group of drugs classified as selective progesterone receptor modulators (SPRM), which block…
